Agreement builds on the companies' ongoing partnership to expand choice and simplify diabetes management

NORTHRIDGE, Calif., June 3, 2026 /CNW/ -- MiniMed (NASDAQ:MMED), a global leader in diabetes technology, today announced an expanded agreement with Abbott to collaborate on commercializing dual glucose-ketone sensors designed to integrate exclusively with MiniMed smart dosing systems.

These new dual monitoring sensors are designed to enable early, real-time detection of rising ketones to help prevent diabetic ketoacidosis (DKA), a life-threatening complication. The agreement builds on the companies' existing partnership for the Instinct sensor, made by Abbott, and will offer MiniMed users expanded choice across its automated insulin delivery and Smart MDI systems. The sensors will be the same size as the Instinct sensor, the world's smallest and thinnest sensor.

The companies expect to provide further updates on regulatory and commercialization milestones in the coming months.

Abbott's dual glucose-ketone systems are not yet cleared or available for sale in the United States.